The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk of osteoporosis/osteopenia events in patients newly diagnosed with neuroendocrine tumors.
J. W. Hill
Research Funding - Novartis
C. Chen
No relevant relationships to disclose
G. P. Hess
No relevant relationships to disclose
Z. Liu
Employment or Leadership Position - Northwest Biotherapeutics
Stock Ownership - Novartis
J. C. Yao
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
A. T. Phan
No relevant relationships to disclose